Aktis Oncology (AKTS) director details IPO-related share conversion

Rhea-AI Filing Summary

Aktis Oncology, Inc. director Segal Lloyd Mitchell reported an automatic conversion of preferred stock into common shares tied to the company’s initial public offering. On 01/12/2026, Arvala, Inc., an entity for which Mitchell is president and sole stockholder, converted 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock into the issuer’s common stock on a 3.8044-for-1 basis without any cash payment. This conversion resulted in 19,631 shares of common stock, all held indirectly through Arvala, Inc., and reflects the automatic conversion that occurred immediately before the closing of the IPO.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Segal Lloyd Mitchell

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		C(1)		19,631	A	(1)	19,631	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Redeemable Convertible Preferred Stock	(3)	01/12/2026		C			50,000	(3)	(3)	Common Stock	13,142	$0	0	I	See Footnote(2)
Series B Redeemable Convertible Preferred Stock	(3)	01/12/2026		C			24,687	(3)	(3)	Common Stock	6,489	$0	0	I	See Footnote(2)

Explanation of Responses:

1. Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration.

2. Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.

3. The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

	/s/ Karen McCarthy, as Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aktis Oncology (AKTS) disclose in this Form 4?

The filing reports that preferred shares held through Arvala, Inc. automatically converted into 19,631 shares of Aktis Oncology common stock in connection with the company’s initial public offering.

Who is the reporting person in this Aktis Oncology (AKTS) Form 4?

The reporting person is Segal Lloyd Mitchell, who serves as a director of Aktis Oncology, Inc. and files the Form 4 as a single reporting person.

Which securities were converted into common stock for Aktis Oncology (AKTS)?

The Form 4 shows 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock automatically converted into common stock on a 3.8044-for-1 basis.

How many Aktis Oncology (AKTS) common shares are held after the reported transaction?

After the conversion, 19,631 shares of Aktis Oncology common stock are reported as beneficially owned, held indirectly through Arvala, Inc.

How is Arvala, Inc. related to the Aktis Oncology (AKTS) director in this filing?

Arvala, Inc. holds the shares. Segal Lloyd Mitchell is described as the president and sole stockholder of Arvala, Inc. and may be deemed to share voting and dispositive power over those shares.

Was any cash paid in the Aktis Oncology (AKTS) preferred stock conversion?

No cash was paid. The filing states that the common shares were received without payment of further consideration upon conversion of the preferred stock.

When did the Aktis Oncology (AKTS) preferred stock convert into common stock?

The Series A and Series B Redeemable Convertible Preferred Stock automatically converted immediately prior to the closing of Aktis Oncology’s initial public offering, with a transaction date of 01/12/2026.